Prime Medicine
Cambridge
About Prime Medicine
Prime Medicine develops gene editing therapies based on Prime Editing, a technology that enables the precise correction of genetic mutations at their source. The company focuses on treating genetic diseases by repairing DNA without making double-strand breaks, offering an alternative to traditional CRISPR approaches. Prime Editing is designed to target and correct a wide variety of mutations, allowing the development of therapeutic programs across multiple organ systems. Prime Medicine's pipeline includes investigational therapies for diseases affecting the liver, eye, blood, and central nervous system. The company integrates its proprietary delivery platforms and screening tools to enhance the specificity and durability of gene edits. Its research and development efforts aim to translate advances in genome editing into clinical applications with the potential for one-time, curative treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $558.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:PRME
- Website: primemedicine.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prime-medicine-124196 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.